Ethical Issues and Risk/Benefit Assessment of Iron Chelation Therapy: Advances with Deferiprone/deferoxamine Combinations and Concerns about the Safety, Efficacy and Costs of Deferasirox [Kontoghiorghes GJ, Hemoglobin 2008; 32(1–2):1–15.]

REFERENCES

• Kontoghiorghes GJ. Ethical issues and risk/benefit assessment of iron chelation therapy: Advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox. Hemoglobin 2008; 32(1–2)1–15
   PubMed Web of Science ®Google Scholar
• Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, Olivieri N, Piga A, Cunningham MJ, Soulieres D, Gattermann N, Tchernia G, Maertens J, Giardina P, Kwaitkowski J, Quarta G, Jeng M, Forni GL, Stadler M, Cario H, Debusscher L, Della Porta M, Cazzola M, Greensberg P, Alimena G, Rabault B, Gathmann I, Ford JM, Alberti D, Rose C. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study. Eur J Haematol 2008; 80(2)168–176
   PubMed Web of Science ®Google Scholar
• Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, Leoni G, Lavagetto A, Zappu A, Longo F, Maseruka H, Hewson N, Sechaud R, Belleli R, Alberti D. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily oral chelating agent, in paediatric patients with β-thalassaemia major. Haematologica 2006; 91(10)1343–1351
   PubMed Web of Science ®Google Scholar
• Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91(7)873–880
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janak-Scahub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 2006; 107(9)3455–3462
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressyer-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136(3)501–508
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Vichinsky E, Galanello R, Piga A, Williamson P, Porter JB. Long-term treatment with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anemias. Blood 2007; 110(11)816b, (Abstract 2777)
   Google Scholar
• Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102(5)1583–1587
   PubMed Web of Science ®Google Scholar
• Brissot P, Deugnier Y, Cianciulli P, Cario H, Jeng M, Rabault B. Correlation between dose-dependent reductions in serum transaminase (ALT) and serum ferritin levels during long-term chelation therapy with deferasirox (Exjade®, ICL670). Blood 2006, 108(11)30b, (Abstract 3817)
   Google Scholar
• http://www.exjade.com, Exjade (deferasirox) Prescribing Information. Novartis Pharmaceuticals Corporation. 2007
   Google Scholar
• Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients. US healthcare system perspective. Pharmacoeconomics 2007; 25(4)329–342
   PubMed Web of Science ®Google Scholar
• Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation?. Arch Intern Med 2003; 163(14)1637–1641
   PubMed Web of Science ®Google Scholar
• Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 2000; 20(3)332–342
   PubMed Web of Science ®Google Scholar
• Lucas GN, Perera BJ, Fonseka EA, De Silva DD, Fernadopulle M, Karunatilaka DH, Weerasinghe I. Experience with the oral iron chelator deferiprone in transfusion-dependent children. Ceylon Med J 2002; 47(4)119–121
   PubMedGoogle Scholar
• Nick H, Wong A, Acklin P, Faller B, Jin Y, Lattmann R, Sergejew T, Hauffe S, Thomas H, Schnebli HP. ICL670A: preclinical profile. Adv Exp Med Biol 2002; 509: 185–203
   PubMed Web of Science ®Google Scholar
• Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major. Blood 2008; 111(2)583–587
   PubMed Web of Science ®Google Scholar
• Glickstein H, Ben El R, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators. A fluorescence study of chelator action in living cells. Blood 2005; 106(9)3242–3250
   PubMed Web of Science ®Google Scholar
• Wood JC, Otto-Duessel M, Gonzales I, Gonzalez I, Aguilar MI, Shimada H, Nick H, Nelson M, Moats R. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Translational Res 2006; 148(5)272–280
   PubMedGoogle Scholar
• Porter JB, Tanner MA, Pennell DJ, Eleftheriou P. Improved myocardial T2* in transfusion dependent anemias receiving ICL670 (deferasirox). Blood 2005; 106(11)1003a, (Abstract 3600)
   PubMedGoogle Scholar
• Taher A, El-Beshlawy A, Al Jefri A, Elalfy M, Al Zir K, Daar S, Damanbouri G, Krahn U, Pfluger D, Hadler D. Treatment with the once-daily, oral iron chelator deferasirox is effective and well tolerated in β-thalassaemia patients with a high iron burden. Haematologica 2007; 92(Suppl 1)302, (Abstract 808)
   Google Scholar
• Wood JC, Otto-Duessel M, Aguilar M, Nick HP, Coates TC, Rex M. Dose response of deferoxamine, deferiprone, and ICL670 chelation therapy in a gerbil model of iron overload. Blood 2004; 104(11)985a, (Abstract 3621)
   Google Scholar
• Cappellini MD, Vichinsky E, Ford JM, Rabault B, Porter J. Evaluation of deferasirox (Exjade®, ICL670) therapy in patients with transfusional iron overload who achieve serum ferritin (SF) <=1000 ng/mL in long-term studies. Blood 2007; 110(11; Suppl 2)16b, (Abstract 3795)
   Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clin Ther 2007; 29(5)909–917
   PubMed Web of Science ®Google Scholar